Is Iovance Biotherapeutics Inc (IOVA) overvalued? · rev $164.1M
Iovance Biotherapeutics Inc (IOVA) is a biotechnology company listed on US.
This page asks whether Iovance Biotherapeutics Inc (IOVA) looks expensive on cached numbers — not a short thesis.
Latest reported IOVA revenue for 2024-12-31 was $164.1M. Net income was -$372.2M. Revenue was up 13699.0% from 2023-12-31 to 2024-12-31. IOVA currently screens at market cap $1.89B.
IOVA currently screens at market cap $1.89B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IOVA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IOVA stock page for the full model, not this heading.
Not investment advice.